This pathway exploits an ancient machinery of innate immunity that protects against pathogens to reinvigorate CD8+ T cell functions in the tumor microenvironment and is therapeutically actionable by a clinically approved demethylating agent. The gene discussed is CD8A; the disease is neoplasm.